Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SMH
Warned you all
I love reading the defenders of this company justify and feed off of hope as the retail get crushed. Company is in the $0.02s and yet they still feed off of people who spend their hard earned dollars, who actually listen to others past and buy into the hype. I know Jason runs a promotion shop in downtown New York and had accounts on platforms like this. This is pathetic knowing people don't care as long as they get their fees.
I most likely will lose hundreds of thousands on todos and yet I warn people. It is in my best interest for the stock to go up and for people to believe and buy yet I go against my own interest off of principals. I know the probability is extremely low. Even if the company makes it one day down the road, you still most likely will get crushed
Look at the history of gc. He doesn't care about you at all.
People post on this board because it can influence readers. People rarely post on big stocks because it doesn't influence.
There are some good Penny stocks and I get the appeal. But come on, this is not ran by a team who is dedicated to their investors. THEY HAVE ALREADY SOLD US ALL OUT!! SHARES ABOVE 2 BILLION. PRICE DOWN 95% UNDER CURRENT MANAGEMENT.
Why are other people threatened to hear adverse perspective?
The company has raised and spent $20+ million of hard dollars, diluted to billions of stock and crashed value.
There is 1 way, to hit milestones, make progress and maintain the integrity of a business thesis/ value proposition.
He has consistently turned his back on his retail base and is out of money. Massive dilution is inevitable and the man does not care about you.
Also, covid is coming to an end and the huge potential revenue never happened. The company will pivot soon and the share count will go way up and be hidden through a reverse.
Much better odds in Vegas.
I warned you all!! I suggest run. I expect to hear from the Hurd from some saying it is about to go to the moon. Meanwhile, the stock goes to billions in shares, and down over 95% since gerald took control. How can you trust this and believe it is about to explode. Covid is almost over and they have no money to drive other assets, and to get that money will be costly. Already showed the world he can't capitalize and he is willing to blow up his retail base to get 1 dollar.
ruuuuunnnn
Why not am acquisition strategy. A lot of cash on hand. Might be a good way to grow.
Added expenses not justifying growth. Looks like they are just paying more salaries with no real plan to grow value for investors.
We have 100k in. Reached out to management and would take a large piece if DD went well. Need to hear more than what we are hearing.
Toxic converts
I wish I believed but how can you trust someone who has already shown their true colors. If he learned, he would not be repeating the same mistakes. Company has dropped 93% since he came in and has issued billions of shares.
Think about that, the companies marketcap is $30ish million while going from 25 million shares to billions and decline from$0.85 to $0.035 and lower. All the dilution has propped the marketcap. Who makes up the marketcap? All the investors who have bought from $.85 to now. That money on volume went somewhere.
The company is bleeding money and counts on bad financing to keep up. They have raised over $20 million and are constantly out of cash. The guys who invested that capital are making money from everyone who buys because they sell.
If they were ramping revenue and even close to a blockbuster, the orbimeds would be pushing $50 million in to get product and distribution to scale.
Do you really think that the company has the capacity to handle scale?
I wish I was wrong but you can't trust the execution at this point imo.
I think AMBS was at one time in a great position. After failing, looking back to see what happened is very important. Looking at the road blocks that many early companies face explains a lot. Many have no capital and feel no choice but to take horrible financing knowing what it will do to their retail investors.
So the question is was gerald a victim who got conned by some bad people who crushed the company or did he know and didn't care? No doubt the man is smart. No doubt he can promote. Was AMBS a tactical flaw or a character flaw. If tactical, can Gerald learn? If character, then how can you trust someone who knowingly will betray you to hit their agenda.
My personal stance given the evidence is it is both. I personally could not take in toxic convertible debt a second time, in a different company after watching it destroy so many of my last investors in AMBS. To be honest, I would jeopardize BK and fight to finance with good investors and funds and make as much progress to attract good investors. They are out there. I would eat McDonald's and sleep in super 8. And I would fail honorable before turning my back on you all and crushing my investor base.
Look at the funding. Follow the money. Watch the big blocks print after close. Those are signs of conversions and the company still issued stock. You had a company with a few million shares go to billions and look to authorize more. All while promoting non stop on Twitter. Why? Because if the volume dries up then the converts can't sell out and finding stops. Company then sits with super protected debt and no clean money will touch it.
Revenue? Go back and look at the splits with the suppliers, and provista. He had no terms at that time and the sales went to them. Very little went to tomdf. Promoting how well and the huge potential revenue and what huge stock jump will be if... lack of astute attention to detail and follow through.
I get hit up non stop asking for people to join my board. Advisors love free stock and salaries. Question is are they really working or just something to showcase on paper? The real players invest when they take seats.
Investing 101, bet on leadership and that means this is investing in gerald. A man who paid himself aggregious bonuses while the company is in default and close to BK.
I once believed. I have done my homework and the stock chart, price drop since gerald started, shares issued, company debt, high salary and bonus, spending habits, not disclosing deal terms, all while still promoting, knowing the truth has changed everything.
Run!!!!
The company will never move forward with this leadership. GC does not care and is sloppy. The company is in default and spends money like they are ballers and are already selling millions of units. They can't capitalize on good terms and have constant problems with their filings. Leadership is content doing toxic convertible notes and for years talk about how they are working to clean it up while they still issue more of the same notes. This has caused the company to issue and dilute the stock of the company to the point where people have lost so much money from their investments, while the note holders convert at a guarantee profit. Maybe worth it if they had 100 million from the raises but they are close to broke and selling noise of promises revenues. What ever happened to the revenue from the testing? Well, they did a deal while not defining terms with provista. This means they sunk large amounts of money into a lab that had nothing special. Gave them most of the revenue and inflated the deal cost when they finally got terms. Almost all that money the company never seen. GC is known for not defining terms and telling the market they have agreed on an acquisition or license deal or partnership. So how this works is he sells shares to people who get crazy discounts and they vote in his favor. He maintains control and gets the most lucrative ceo deal with crazy bonuses and equity while he has not performed at all. Company is close to no cash and what cash he does have her pays himself and spends uncontrollable while failing to report terms, transactions, detailed expenditures. No real governance. No care about the retail investors. All while constantly tweeting about how great and close they are. He is wonderful at promoting. Doing the exact same thing they did at AMBS and has not learned his lesson. You will get crushed here. Only people playing this are technical traders riding variance. Fundamentalist play short. All the covid companies actually doing something are not sitting with crazy debt, no cash, limited sales and spending their time just promoting.
Is leadership trying to grow value and build something special or just collecting salaries?
Yes but we need to understand those numbers precisely to this specific virus. It would not work with 80 and 82 percent as other test that are currently being used are much higher. The banger would be a swab home test kit but how do we scale? The government would be the buyer but accessibility and timeliness are most important. There is a lot of competition driving the same race. First step is making sure this test is conclusive.
Where did you get the specificity and sensitivity numbers?
Thank you in advance
This is structured to be a bridge to a larger closing. This limits the selling of the stock and also allows us to roll these investments into the larger transaction. Hence short term limiting the dilution. Also this is the start of us buying out the groups current instruments while giving the company operating capital. All in all it is a much needed start to a new beginning for Amarantus.
Equity Building Financing expected to payoff
The long expected pipeline and team is finally here. Necessary financing expected to move the pipeline closer to approval. With trials on its way, moving the assets provide potential for partnerships or sale.
Genius Financing creates value yet again
Acquisition of MS Precise brings potential to generate revenue. This Genius play from Gerald and team comes with a $7.5mm New Jersey Tax credit that nearly pays for itself. This potential revenue generator is 12-24 months from providing cashflow. Multiple Sclerosis diagnostics across the industry has the potential to generate $400mm in the US alone and will be a huge saving to our tax payers by increasing the accuracy and limiting misdiagnosis.
Genius Financing creates value yet again
Acquisition of MS Precise brings potential to generate revenue. This Genius play from Gerald and team comes with a $7.5mm New Jersey Tax credit that nearly pays for itself. This potential revenue generator is 12-24 months from providing cashflow. Multiple Sclerosis diagnostics across the industry has the potential to generate $400mm in the US alone and will be a huge saving to our tax payers by increasing the accuracy and limiting misdiagnosis.
Equity Building Financing expected to payoff
The long expected pipeline and team is finally here. Necessary financing expected to move the pipeline closer to approval. With trials on its way, moving the assets provide potential for partnerships or sale.
Dilutive Financing Builds Equity
Financing creates needed cash flow to Acquire ESS bringing another asset into Amarantus. This dilution creates value by adding to the already robust pipeline. ESS former company once had a marketcap of over $150mm with no other assets. Trials expected to start soon.
Equity Building Financing expected to payoff
The long expected pipeline and team is finally here. Necessary financing expected to move the pipeline closer to approval. With trials on its way, moving the assets provide potential for partnerships or sale.
David H. Ahrenholz, former president of the American Burn Association, spoke today at the shareholder meeting. At one point he was in tears talking about a few of his patients. When asked after the meeting why he got choked up, he said because he lost these patients and knew that this product could of saved their lives!!
This is why we invest- to bring life saving technologies to the forefront and hopefully get financially rewarded while doing so!
Genius Financing creates value yet again
Acquisition of MS Precise brings potential to generate revenue. This Genius play from Gerald and team comes with a $7.5mm New Jersey Tax credit that nearly pays for itself. This potential revenue generator is 12-24 months from providing cashflow. Multiple Sclerosis diagnostics across the industry has the potential to generate $400mm in the US alone and will be a huge saving to our tax payers by increasing the accuracy and limiting misdiagnosis.
Dilutive Financing Builds Equity
Financing creates needed cash flow to Acquire ESS bringing another asset into Amarantus. This dilution creates value by adding to the already robust pipeline. ESS former company once had a marketcap of over $150mm with no other assets. Trials expected to start soon.
Thank you for your suggestion!
All excellent questions! It is hard to gauge wall street since many institutions have strict guidelines on investing criteria. We will see a lot more on how amarantus is viewed on wall street after the uplist and at the start of the ess. Really look at the public institutions that have to release their holdings. Remember we have in the past had two disclosers from major institutions stating they may or may not buy, including Fidelity. I would love to see a good partnership and wonder if they have been approached by offers and the company declined waiting to build more value. I think we are getting close to this point. If we get some good data back from either ess or eltropozine on the phase 2b I think we will get the partnership we have been waiting for.
I think Gerald is very eager which is good but also presents challenges. His eagerness has really done a good job diversifying the company. He is now going to have to be precise and execute. I am not too concerned with the dilution because I feel we have gained a lot of value from the money and shares spent. ESS cost a lot of our cash and shares but in my opinion was a steal. Also to note that the company most likely won't be diluting us to buy anymore products any time soon and further dilution (yes we will be diluted further) will provide necessary capital to uplist and move the products forward.
I also would like to hear more from their solid board but when I see us getting publications and getting orphan status and see data then I know they are working hard. That stuff is not easy and is essential to create value and the eye of both doctors and big pharma.
Gerald's performance has been nothing short of spectacular. He has done more since founding the company then anyone would of ever thought. I personally think that NASDAQ oriented institutions are thinking that they wished he worked for them. Remember that these institutions know how to play the game and are the best in the industry at buying cheap shares.
All excellent questions! It is hard to gauge wall street since many institutions have strict guidelines on investing criteria. We will see a lot more on how amarantus is viewed on wall street after the uplist and at the start of the ess. Really look at the public institutions that have to release their holdings. Remember we have in the past had two disclosers from major institutions stating they may or may not buy, including Fidelity. I would love to see a good partnership and wonder if they have been approached by offers and the company declined waiting to build more value. I think we are getting close to this point. If we get some good data back from either ess or eltropozine on the phase 2b I think we will get the partnership we have been waiting for.
I think Gerald is very eager which is good but also presents challenges. His eagerness has really done a good job diversifying the company. He is now going to have to be precise and execute. I am not too concerned with the dilution because I feel we have gained a lot of value from the money and shares spent. ESS cost a lot of our cash and shares but in my opinion was a steal. Also to note that the company most likely won't be diluting us to buy anymore products any time soon and further dilution (yes we will be diluted further) will provide necessary capital to uplist and move the products forward.
I also would like to hear more from their solid board but when I see us getting publications and getting orphan status and see data then I know they are working hard. That stuff is not easy and is essential to create value and the eye of both doctors and big pharma.
Gerald's performance has been nothing short of spectacular. He has done more since founding the company then anyone would of ever thought. I personally think that NASDAQ oriented institutions are thinking that they wished he worked for them. Remember that these institutions know how to play the game and are the best in the industry at buying cheap shares.
Gerald and John Commissiong are constantly getting accused of being liars. This is far from the case. I would argue that Gerald Commissiong is Amarantus. In just a few years lets see what Gerald has managed to pull off. He has spent the last few years positioning MANF for clinicals while adding not one but two robust divisions. The therapeutics division has been slowly building a pipeline of potential blockbuster therapeutics.
The acquisition of Eltropozine was essential in the diversification of the company and the phase 2b trial has already dosed their first patient in only one of the indicators that the potential treatment will be used for. You can anticipate that good data from this study wont only get the attention of big pharma but they will be ready to bring their check books with them. Any partnership will most likely open up the company to going after the other indications that eltropizine has the ability to treat. Good data will also bring in more attention that could result in institutions bringing their checkbooks too!
ESS is just brilliant. Yes there has been trouble around this asset but not because the asset doesn't work. Rather the trials were mismanaged. What does this create? Opportunity! And Gerald ceased it- He recently finalized the acquisition and managed to do this for pennies on the dollar. With trials slated to start in either Q3 or Q4 look to see a steady update on how the effectiveness of ESS is performing. If it is close to what its potential is then we will see in my opinion national attention.
MANF is still brewing. This protein has a lot of hype and excitement around it. Gaining an International Interest, it will be costly to get this developed to the point of commercialization but with a little work it can be done. The key is to not give it away too early. Management has already done a great job on building its value by gaining multiple orphans indications and aligning partnerships with key universities to continue building its value by gaining multiple orphans indications and aligning partnerships with key universities to continue building the program. This potential blockbuster could create Amarantus into one of the pharmaceutical juggernauts. If a trial is successfully completed then watch out for large pharmaceuticals to do anything they can to get their hands on it!
Sounds like a lot?!? Well, Gerald was just warming up. He recently has created Amarantus DX. They boost that this will be the most robust neurological diagnostic line of assets ever assembled inside of one company. Many ways to play this and it will be interesting to see if he spins this out or keeps it in house. But you can beat that the company is working on it. With acceptance of data into major journals, the word about MS Precise is getting out there. The result is that Amarantus was able to attract a top advisory board with high levels of industry experience to the company. From Dr. Goix to Dr. Wand to Mr. Guillen their expertise and connections reaches through the heart of the diagnostic community. Raising over $70mm in equity capital, Dr. Giox also developed revenues of over $60mm annually. Why would they join? One would speculate that they see the potential of the assets.
On the doorstep of commercialization, MS Precise is ready to run through. Yes, it will take a few years to maximize revenue but the process is started and there are plans to have this hit commercialization soon. The recent journal news shows that the medical community is taking note and will give doctors the confidence they need to one day use the diagnostic.
Lympro has been constantly criticized on the message boards and shareholders seem very confused on this asset. The recent data released has shown consistency and if this consistency is further supported by PET imaging then it could be special. The first customer has been brought in and if a heavy hitter comes in and uses Lympro then we can expect others will follow.
The Georgetown Assays are also in the mix and you can bet that the newly assembled teams will be eager to further develop these assays and complete the acquisition.
This is a lot and I would argue that Gerald is the best one for the job. After all he has raised enough capital to get us where we are and built solid enough connections for people to trust him enough to sell him these assets. These companies all have back end incentives for Gerald to be successful and wouldn't sell them to just anyone.
http://www.amarantus.com/news/press-releases/detail/2009/amarantus-announces-publication-of-a-clinical-study-of
huge news that was over looked. Scientific journals= getting doctors interested and provides credibility.
Publications are essential to validating and creating awareness and the process to get your work published is strictly reviewed and analyzed before acceptance. Hard work is paying off!
I have had a lot of calls and see people very concerned about the state of AMBS. I am open to receiving phone calls to discuss our firm's view of AMBS. All discussed will be opinion but willing to discuss over the weekend.
Team international infusion-
You can find info at our website
Because the people on these blogs have done a good job at creating panic where there should be none.
Gerald has built AMBS, it's asset base, it's management team and has made AMBS one of the most watched new bio pharmaceutical companies. He has attracted analyst and raised enough capital to get the company to the point where they can execute. At the end of the day we are one step closer to moving our product line into the hands of the doctors where they can save lives.
Also, with the new cusip number the shorts have to cover. Hence that's why there is so much buying along with the selling.
I disagree. This is a brilliant decision and a clear pathway to the NSDQ!
I think that they will be on the NSDQ inside of 60-90 days.
I have had a few dozen calls from people inquiring my thoughts on the split. I will say that I am super excited about the direction of AMBS. With International Infusion being one of the major shareholders of the stock, I am happy to see the company executing on its current plan to be listed on the NSDQ. We have clinicals starting for our phase 2b this quarter and we are with finalizing the acquisition of ESS. This reverse is going to allow the pathway for major institutions to invest and we have already had disclaimers in the past from JP Morgan and Fidelity. The float is going to be much more lean which is going to help control volatility. As the maker institutions buying substantial parts of the float we will see more consistency in our price points. Another thing people constantly ask is about the dilution. This is a bio tech and is going to have dilution which does create value by giving the necessary resources to make acquisitions and advance the programs. You can count on the two billion shares to one day be used. If you double the share count which also doubles the market cap we are still way below the value of 180mm which zacks evaluated us at. And remember that valuation is without ESS and without consideration of trials starting for both ESS and eltropozine. People also have asked about cash flow concerns. Remember this quarterly report does not show the $5mm that was just raised and worse case we have $12mm left on the equity line. There have been a lot of strides over the past few years and we truly are a diversified bio company with some iconic names in the space. Simply put, when the institutions buy it is going to be a lot more difficult to get those shares from them.
Here comes the funds!!!! Booooom baby boooooooom!
Looks like payment is made and the lawsuit is being dismissed!